Fosun Pharma Reports Significant Financial Growth in Q3 2025
Fosun Pharma Reports Significant Financial Growth in Q3 2025
On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., commonly known as Fosun Pharma, announced its financial performance for the first three quarters of 2025. Renowned for its commitment to innovation within the global healthcare sector, Fosun Pharma achieved remarkable results that underscore its steadfast growth trajectory.
Key Financial Highlights
In the first three quarters of 2025, Fosun Pharma recorded operating revenue of RMB 29,393 million. This figure marks a robust performance driven largely by the company's innovative drugs pipeline, which generated over RMB 6,700 million, reflecting an 18.09% increase compared to the previous period. The net profit attributable to shareholders reached RMB 2,523 million, signaling a positive reinforcement of the company’s financial health. Fosun Pharma's commitment to enhancing operational efficiency is evident as reflected by their substantial net cash flow from operating activities, totaling RMB 3,382 million, a 13.23% increase, further indicating an improved operational quality.
Focus on Innovative Products
Fosun Pharma is strategically focused on advancing its innovative product portfolio, zeroing in on critical therapeutic domains such as solid tumors, hematologic cancers, and immune-inflammatory diseases. The company is leveraging core technology platforms, which include antibodies, antibody-drug conjugates (ADCs), cell therapy, and small molecules. In Q3 2025, several of Fosun Pharma's self-developed drugs reached significant milestones:
- An additional indication for the Fovinaciclib Citrate Capsules, a novel small molecule CDK4/6 inhibitor, received approval in mainland China, broadening treatment options for hormone receptor-positive, HER2-negative breast cancer patients.
- The denosumab injection, identified as HLX14, marked a historic launch as the first domestically developed drug of its kind to receive approval for the U.S. and European markets, expanding therapeutic options for bone loss-related ailments.
- Fosun's hematology division saw the acceptance of the registration application for Brexucabtagene Autoleucel Injection, targeting relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Enhancing Innovation Capabilities
Fosun Pharma is dedicated to sustainable, innovation-driven growth, characterized by the meticulous allocation of R&D resources. The company's R&D investment for the first three quarters stood at RMB 3,998 million, a modest increase of 2.12% from the previous year, while the R&D expenses for Q3 alone reached RMB 1,013 million, demonstrating 28.81% year-over-year growth. This investment is primarily directed toward cutting-edge technology, including radiopharmaceuticals and cell therapies, highlighting Fosun Pharma's commitment to pioneering the development of high-value pipelines.
Prominent advancements in clinical trials were made with the company’s innovative anti-PD-1 monoclonal antibody, Han Si Zhuang, which is making promising strides across multiple conditions. Notably, the Phase 3 clinical study for its application in gastric cancer has achieved its primary endpoints, with regulatory filings anticipated soon to introduce this key treatment to market.
Strategic Bond Issuance
Moreover, Fosun Pharma successfully issued RMB 1 billion in medium-to-long-term Sci-Tech innovation bonds, becoming the first private pharmaceutical entity to do so under a recent initiative by the People's Bank of China. This move will bolster its funding capabilities, further enabling Fosun Pharma to explore significant scientific innovations more effectively.
Through these strategic ventures and continuous focus on research and development, Fosun Pharma aims to provide accessible healthcare solutions that elevate treatment standards globally. With an eye towards the future, the company remains true to its core mission of delivering high-quality healthcare products, committed to enhancing global health outcomes.
About Fosun Pharma
Established in 1994, Fosun Pharma has systematically integrated its operations within the global healthcare landscape, driven by its core values of innovation and collaboration. By focusing on major therapeutic areas and leveraging advanced technologies, Fosun Pharma positions itself to continue leading in pharmaceutical innovation, ensuring better healthcare for communities worldwide.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.